MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.
Primary Inclusion Criteria:
Primary Exclusion Criteria: